NGM Biopharmaceuticals
Stock Forecast, Prediction & Price Target
NGM Biopharmaceuticals Financial Estimates
NGM Biopharmaceuticals Revenue Estimates
NGM Biopharmaceuticals EBITDA Estimates
NGM Biopharmaceuticals Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $77.88M N/A | $55.33M -28.95% | $4.41M -92.01% | Avg: $100K Low: $100K High: $100K avg. -97.73% | Avg: $8.91M Low: $8.91M High: $8.91M avg. 8819.75% | Avg: $29.6M Low: $29.6M High: $29.6M avg. 231.84% | Avg: $71.7M Low: $71.7M High: $71.7M avg. 142.22% |
Net Income
% change YoY
| $-113.82M N/A | $-159.08M -39.76% | $-142.37M 10.50% | Avg: $-94.25M Low: $-88.27M High: $-31.34M avg. 33.80% | Avg: $-89.79M Low: $-84.14M High: $-70.12M avg. 4.73% | Avg: $-64.34M Low: $-64.34M High: $-64.34M avg. 28.33% | Avg: $-51.14M Low: $-51.14M High: $-51.14M avg. 20.51% |
EBITDA
% change YoY
| $-120.69M N/A | $-166.24M -37.74% | $-144.32M 13.18% | Avg: $-89.53K Low: $-89.53K High: $-89.53K avg. 99.93% | Avg: $-7.98M Low: $-7.98M High: $-7.98M avg. -8819.77% | Avg: $-26.50M Low: $-26.50M High: $-26.50M avg. -231.84% | Avg: $-64.19M Low: $-64.19M High: $-64.19M avg. -142.22% |
EPS
% change YoY
| -$1.48 N/A | -$1.99 -34.45% | -$1.73 13.06% | Avg: -$0.78 Low: -$1.07 High: -$0.38 avg. 54.91% | Avg: -$0.94 Low: -$1.02 High: -$0.85 avg. -19.87% | Avg: -$0.78 Low: -$0.78 High: -$0.78 avg. 16.57% | Avg: -$0.62 Low: -$0.62 High: -$0.62 avg. 20.51% |
Operating Expenses
% change YoY
| $198.57M N/A | $221.58M 11.58% | $148.74M -32.87% | Avg: $201.24K Low: $201.24K High: $201.24K avg. -99.86% | Avg: $17.95M Low: $17.95M High: $17.95M avg. 8819.75% | Avg: $59.56M Low: $59.56M High: $59.56M avg. 231.84% | Avg: $144.29M Low: $144.29M High: $144.29M avg. 142.22% |
FAQ
What is NGM Biopharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 21.84% in 2025-2028.
We have gathered data from 2 analysts. Their low estimate is -88.27M, average is -94.25M and high is -31.34M.
What is NGM Biopharmaceuticals stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 2274.02% in 2025-2028.
We have gathered data from 5 analysts. Their low revenue estimate is $100K, average is $100K and high is $100K.
What is NGM Biopharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 18.03% in 2025-2028.
We have gathered data from 2 analysts. Their low earnings per share estimate is -$1.07, average is -$0.78 and high is $-0.38.
What is the best performing analyst?
In the last twelve months analysts have been covering NGM Biopharmaceuticals stock. The most successful analyst is Steven Seedhouse whose win rate is 100%. He has correctly predicted 1/1 price targets.